

Mama

The Monoclonal Antibody Medications in inflammatory Arthritis: stopping or continuing in pregnancy (MAMA) study

The MAMA study is for pregnant women under 28 weeks' gestation who are on a biologic for inflammatory arthritis

We are comparing two pathways of care:

Continuing biologics throughout pregnancy

OR

Stopping biologics before 28 weeks gestation and restarting no earlier than 2 weeks post-pregnancy

If you would like to find out more information, please talk to a member of your clinical care team



Please scan the QR code to watch the video.

www.npeu.ox.ac.uk/mama

This study is funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme (Reference Number NIHR153577). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.